#AKYA

Savunma360.com

@savunma360.bsky.social

5 months ago

🎯 Yerli Torpido AKYA’da Büyük Başarı!
Milli torpidomuz AKYA, artık 54 atış geride bıraktı.

⚓️ TCG PREVEZE’den ateşlenen AKYA, 12.000 yarda mesafeden hedefini tam isabetle vurdu!

#SavunmaSanayii #AKYA #Denizaltı #MilliGüç

StockTitan

@stocktitan.net

9 months ago

Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal Kent Lake, holding 6.9% of Quanterix (QTRX) shares, responds to developments in the proposed merger with Akoya Biosciences (AKYA). The key points include: 1. Akoya received an unsolicited all-cash offer of $1.40 per share, representing a 22% premium over both Akoya's 30-day VWAP and Quanterix's implied offer. 2. Quanterix's amended merger terms, which bypass shareholder voting, include $20 million in cash and 8.4 million new shares. 3. Quanterix trades at $4.75 per share, below its net cash position, with a negative enterprise value of $80 million. Kent Lake strongly opposes any increase in Quanterix's offer, citing concerns about value destruction, balance sheet risks, and management's unrealistic break-even projections for 2026, especially given the combined companies' current $80 million burn rate.

#AKYA #QTRX Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

www.stocktitan.net/news/AKYA/kent-lake-resp...

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

Small-cap stocks with strong volume gains, Wed May 21st - #TCRX #CREX #EDBL #MRM #NUKK #SGMA #NIU #LTRY #LAES #IDN #GCL #CPSH #BDSX #AKYA #GOOS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

10 months ago

Akoya Biosciences Reports First Quarter 2025 Financial Results Akoya Biosciences (NASDAQ: AKYA) reported its Q1 2025 financial results, showing a revenue decline of 9.8% to $16.6 million compared to $18.4 million in Q1 2024. Despite lower revenue, the company improved its gross margin to 59.3% from 45.7% year-over-year. Operating expenses decreased by 22.3% to $23.3 million, leading to a reduced operating loss of $13.4 million, a 37.9% improvement. The company ended Q1 with $27.5 million in cash and equivalents. Akoya's installed base grew 12% year-over-year to 1,359 instruments. Notable achievements include the selection of PhenoCycler-Fusion for a Cancer Grand Challenges study and partnership with Singapore Translational Cancer Consortium. The company is currently in the process of being acquired by Quanterix Corporation.

#AKYA Akoya Biosciences Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/AKYA/akoya-bioscien...

StockTitan

@stocktitan.net

10 months ago

Quanterix Slashes Share Issuance in Amended Akoya Merger Deal: Key Changes Revealed Quanterix reduces share issuance by 9M+ in revised Akoya merger. New terms include $20M cash + 7.76M shares. Strong shareholder backing secured. See full details.

#QTRX #AKYA Quanterix and Akoya Biosciences Announce Amended Merger Agreement

www.stocktitan.net/news/QTRX/quanterix-and-...

StockTitan

@stocktitan.net

10 months ago

Major Cancer Research Breakthrough: How 200 Patient Study Could Transform Immunotherapy Treatment Success Groundbreaking pan-cancer study analyzes 200 patients to unlock immunotherapy response patterns. New spatial proteomic analysis could revolutionize treatment. See findings.

#AKYA Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore

www.stocktitan.net/news/AKYA/akoya-bioscien...

StockTitan

@stocktitan.net

11 months ago

Quanterix Under Fire: Top Investor Warns of 'Value Destructive' $30M Deal with Struggling Akoya Kent Lake condemns Quanterix's $30M convertible notes deal with Akoya as risky 'backdoor financing.' Urges shareholders to reject merger proposals. Full analysis inside.

#QTRX #AKYA Kent Lake Comments on Quanterix’s Value Destructive Bridge Financing for Financially Troubled Akoya

www.stocktitan.net/news/QTRX/kent-lake-comm...

StockTitan

@stocktitan.net

11 months ago

Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results Akoya Biosciences (NASDAQ: AKYA) reported its Q4 and full-year 2024 financial results, showing mixed performance in a challenging market environment. Q4 revenue decreased 19.4% to $21.3 million, while gross margin improved to 67.4% from 62.7% year-over-year.Full-year 2024 revenue was $81.7 million, down 15.5% from 2023. The company achieved notable operational improvements, reducing operating expenses by 22.9% in Q4 to $20.1 million. The installed base grew to 1,330 instruments, a 12.4% increase, while publications citing Akoya's technology rose 49.4% to 1,733.Significantly, Akoya announced its pending acquisition by Quanterix (NASDAQ: QTRX), aiming to create an integrated solution for blood and tissue-based protein biomarkers. The company also secured an exclusive global license with NeraCare for the Immunoprint test for melanoma treatment decisions.

#AKYA Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

www.stocktitan.net/news/AKYA/akoya-reports-...

StockTitan

@stocktitan.net

11 months ago

Quanterix Merger Under Fire: Top Investor Reveals Shocking 82% Value Disparity Kent Lake challenges Quanterix-Akoya merger, citing unfair valuation split, governance concerns, and NIH funding risks. Key investor demands answers on controversial deal structure.

#QTRX #AKYA Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today’s Earnings Call

www.stocktitan.net/news/QTRX/kent-lake-urge...

StockTitan

@stocktitan.net

1 year ago

Quanterix Merger Under Fire: 7.25% Stakeholder Reveals Shocking Valuation Concerns Kent Lake challenges Quanterix-Akoya merger, citing 40% stock decline and questionable $30M financing. Key investor presents alternative growth strategy focusing on Alzheimer's testing.

#QTRX #AKYA Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix’s Proposed Merger with Akoya Biosciences

www.stocktitan.net/news/QTRX/kent-lake-issu...

StockTitan

@stocktitan.net

1 year ago

Quanterix Merger Battle: 5.9% Stakeholder Reveals Why $42M Deal Could Destroy Shareholder Value Kent Lake Capital slams proposed Akoya merger, highlighting Quanterix's superior revenue and Alzheimer's potential. Calls for alternatives including $1B+ sale exploration.

#QTRX #AKYA Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company’s Proposed Merger with Akoya Biosciences

www.stocktitan.net/news/QTRX/kent-lake-issu...

StockTitan

@stocktitan.net

1 year ago

Revolutionary Neurobiology Panels: Akoya's New Weapon Against Brain Disease Research Akoya Biosciences unveils strategic roadmap for ultrahigh-plex neurobiology panels, expanding from successful IO60 launch to tackle neurodegenerative diseases with PhenoCycler-Fusion platform.

#AKYA Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels

www.stocktitan.net/news/AKYA/akoya-bioscien...

StockTitan

@stocktitan.net

1 year ago

Major Breakthrough: Akoya's Advanced Diagnostic Tech Gets Manufacturing Powerhouse Backing Akoya Biosciences expands partnership with Argonaut Manufacturing Services to produce IVD diagnostic assays, leveraging cGMP expertise for precision medicine advancement.

#AKYA Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner

www.stocktitan.net/news/AKYA/akoya-bioscien...

Thiard News@F4F

@newsen.bsky.social

1 year ago

Halper Sadeh LLC Leads Investor Investigations for SSTK, AKYA, and POAI Shareholders Halper Sadeh LLC is actively investigating potential violations involving SSTK, AKYA, and POAI. Shareholders can explore their rights and options.

Halper Sadeh LLC Leads Investor Investigations for SSTK, AKYA, and POAI Shareholders #United_States #New_York #SSTK #AKYA #POAI

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #AKYA ) Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

StockTitan

@stocktitan.net

1 year ago

Quanterix to Acquire Akoya in Groundbreaking Biomarker Platform Merger, $40M Synergies Expected Quanterix merges with Akoya Biosciences in all-stock deal, creating first integrated blood and tissue biomarker platform. Combined $220M revenue and $175M cash position strengthen market presence.

#QTRX #AKYA Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

www.stocktitan.net/news/QTRX/quanterix-to-a...

StockTitan

@stocktitan.net

1 year ago

#AKYA Akoya Biosciences Reports Third Quarter 2024 Financial Results

www.stocktitan.net/news/AKYA/akoya-bioscien...

Market Wire News

@marketwirenews.com

1 year ago

News; ( NASDAQ: #AKYA ) Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode(TM) Discovery IO60 and Mouse FFPE IO Panel

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #AKYA ) Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy

#StockMarket #News